Ultragenyx Pharmaceutical (NASDAQ:RARE) has been given a $80.00 target price by equities researchers at Canaccord Genuity in a report released on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s price objective indicates a potential upside of 64.00% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus reissued a “buy” rating and issued a $85.00 target price (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. JMP Securities cut their target price on shares of Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 23rd. Leerink Swann reissued an “outperform” rating and issued a $83.00 target price (down previously from $89.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. Barclays raised their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, Cowen reissued an “outperform” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $72.40.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $48.78 on Tuesday. Ultragenyx Pharmaceutical has a twelve month low of $44.02 and a twelve month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($1.87). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. During the same period in the prior year, the business earned ($1.64) EPS. The business’s revenue was up 81.8% on a year-over-year basis. equities analysts predict that Ultragenyx Pharmaceutical will post -7.26 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of RARE. AXA boosted its stake in Ultragenyx Pharmaceutical by 12.2% in the 3rd quarter. AXA now owns 265,408 shares of the biopharmaceutical company’s stock worth $14,136,000 after purchasing an additional 28,755 shares during the period. California Public Employees Retirement System boosted its stake in Ultragenyx Pharmaceutical by 3.1% in the 3rd quarter. California Public Employees Retirement System now owns 40,300 shares of the biopharmaceutical company’s stock worth $2,146,000 after purchasing an additional 1,200 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Ultragenyx Pharmaceutical by 66.7% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 9,287 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 3,717 shares during the period. Capital International Investors boosted its stake in Ultragenyx Pharmaceutical by 21.9% in the 3rd quarter. Capital International Investors now owns 2,895,481 shares of the biopharmaceutical company’s stock worth $154,213,000 after purchasing an additional 520,496 shares during the period. Finally, Capital Guardian Trust Co. boosted its stake in Ultragenyx Pharmaceutical by 1.7% in the 3rd quarter. Capital Guardian Trust Co. now owns 521,035 shares of the biopharmaceutical company’s stock worth $27,750,000 after purchasing an additional 8,605 shares during the period. Hedge funds and other institutional investors own 94.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Ultragenyx Pharmaceutical (RARE) Given a $80.00 Price Target by Canaccord Genuity Analysts” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/12/07/ultragenyx-pharmaceutical-rare-given-a-80-00-price-target-by-canaccord-genuity-analysts.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.